Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Rybelsus mimics GLP-1 by slowing gastric and gallbladder emptying, which can lead to bile stasis, sludge or stones and biliary pain in up to 5% of users, especially those with rapid weight loss or existing risk factors.
Deciding whether to stay on Rybelsus or switch to another medication involves weighing its benefits for blood sugar control, weight loss and cardiovascular protection against recurrent pain or ultrasound confirmed gallstones. There are several factors to consider; see below for more details to guide your next steps.
Rybelsus (oral semaglutide) is a popular GLP-1 receptor agonist used to control blood sugar in type 2 diabetes. While many patients benefit from its glucose-lowering effects and possible weight loss, some report gallbladder pain or gallstones. If you’ve wondered “why does Rybelsus cause gallbladder pain?” this guide breaks down the science, symptoms, risk factors and what to do next—without sugar-coating or inducing unnecessary anxiety.
Rybelsus mimics the hormone GLP-1 (glucagon-like peptide-1), which:
The slowing of stomach and intestinal transit isn’t limited to food. It also affects the gallbladder by:
Over time, this stasis can lead to gallbladder pain (biliary colic) or acute gallbladder inflammation (cholecystitis).
Several factors explain why Rybelsus may lead to gallbladder discomfort:
Delayed Gallbladder Emptying
GLP-1 receptor agonists slow gallbladder contractions, so bile pools rather than being released regularly into the intestine.
Rapid Weight Loss
Many patients lose weight on Rybelsus. Rapid weight loss (more than 1.5–2 pounds per week) is a known risk factor for gallstones, as it alters cholesterol balance in bile.
Changes in Bile Composition
Slower bile flow allows cholesterol to supersaturate and crystallize, forming sludge or stones.
Pre-existing Risk Factors
Age, female sex, family history of gallstones, obesity and certain blood lipid profiles can combine with Rybelsus effects to heighten pain risk.
Clinical trial data from the PIONEER series and real-world reports suggest:
Gallbladder pain typically presents as:
If you develop fever, persistent vomiting, or signs of jaundice, treat these as potentially serious and speak to a doctor right away.
Deciding whether to switch from Rybelsus involves balancing benefits and risks:
Benefits of Staying on Rybelsus
Reasons to Consider a Change
Alternatives to Discuss with Your Doctor
If you and your doctor decide to continue Rybelsus, consider these strategies to reduce gallbladder strain:
Even mild gallbladder pain can signal gallstones or inflammation. Reach out to a healthcare provider if you experience:
You can also try a free, online symptom check for to gather more information before your appointment.
Before making any medication changes, have a detailed conversation with your healthcare provider. Be prepared to discuss:
Together, you can weigh the benefits of Rybelsus against your gallbladder risks and choose the safest, most effective diabetes management plan.
If you experience severe symptoms or anything that could be life threatening, speak to a doctor immediately. Regular follow-ups and personalized care will keep your diabetes management safe and effective.
(References)
* Zhang J, Ma J, Wang Y, Hu H. Risk of Biliary Disorders with Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Pharmacol. 2023 Nov;63(11):1276-1284. doi: 10.1002/jcph.2343. Epub 2023 Aug 24. PMID: 37624119. https://pubmed.ncbi.nlm.nih.gov/37624119/
* Li L, Xu M, Zhao Z, Cui G, Zheng F, Li Z. Cholelithiasis and Cholecystitis Associated with Semaglutide: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS). Front Pharmacol. 2022 Jul 5;13:920899. doi: 10.3389/fphar.2022.920899. eCollection 2022. PMID: 35799307. https://pubmed.ncbi.nlm.nih.gov/35799307/
* Xiao J, Wu X, Wang J, Chen S, Deng D. Cholecystitis and Cholelithiasis with Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis. J Clin Pharmacol. 2023 May;63(5):561-570. doi: 10.1002/jcph.2201. Epub 2023 Mar 15. PMID: 36915004. https://pubmed.ncbi.nlm.nih.gov/36915004/
* Wang J, Wu X, Sun H, Deng D. Impact of glucagon-like peptide-1 receptor agonists on gallbladder diseases: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022 Jun;47(6):835-846. doi: 10.1111/jcpt.13626. Epub 2022 Apr 1. PMID: 35368307. https://pubmed.ncbi.nlm.nih.gov/35368307/
* Yu K, Xu M, Li L, Sun Z, Zhao Z. Risk of cholelithiasis and cholecystitis with glucagon-like peptide-1 receptor agonists: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2022 Oct;31(10):1135-1146. doi: 10.1002/pds.5513. Epub 2022 Sep 10. PMID: 35923507. https://pubmed.ncbi.nlm.nih.gov/35923507/
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.